Jak Inhibitor-Naive Myelofibrosis

SAN DIEGO — Lower platelet count was identified as a significant predictor for ruxolitinib-induced moderate or severe thrombocytopenia in patients with myelofibrosis, according to research presented at ASH Annual Meeting and Exposition.

The combination of pelabresib plus ruxolitinib significantly increased the proportion of patients with myelofibrosis who achieved a clinically meaningful reduction in spleen volume, according to the agent’s manufacturer.